VYNE Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VYNE research report →
Range $5.75 – $5.75
Price Chart
About the company
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris.
- CEO
- David T. Domzalski
- IPO
- 2018
- Employees
- 10
- HQ
- Stewartsville, NJ, US
Get TickerSpark's AI analysis on VYNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.07M
- P/E
- -0.93
- PEG
- -0.01
- P/S
- 432.69
- P/B
- 1.21
- EV/EBITDA
- 6.31
- Div Yield
- 140.07%
- Gross Margin
- 96.17%
- Op Margin
- -7309.90%
- Net Margin
- -6758.15%
- ROE
- -24.74%
- ROIC
- -8.55%
Latest fiscal year · YoY change
- Revenue
- $570.00K+13.8%
- Gross Profit
- $547.00K+9.2%
- Op Income
- $-29,749,000
- Net Income
- $-26,483,000+33.5%
- EPS
- $-31.00+34.0%
- OCF Growth
- +2.5%
- FCF Growth
- +2.8%
- 52W High
- $74.47
- 52W Low
- $14.03
- 50D MA
- $34.03
- 200D MA
- $28.60
- Beta
- 2.01
- RSI (14)
- 40
- Avg Volume
- 16.91K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
VYNE reported modest third-quarter revenue, narrowed adjusted operating expenses, and said its turnaround is now centered on advancing BET inhibitor assets and FMX114 while pursuing a minocycline-franchise sale.· November 10, 2021
- Q3 revenue was $4.1 million, with $4.0 million from AMZEEQ and ZILXI product sales and $21 million of royalty revenue.
- GAAP net loss was $21.3 million, or $0.41 per share; adjusted net loss was $18.9 million, or $0.36 per share.
- Adjusted operating expenses were $18.4 million, down $1.9 million sequentially, and management expects $10 to $15 million in Q4 2021 excluding a one-time $4 million VYN202 milestone payment.
- Cash was approximately $53 million at September 30, and management said that should fund operations through Q2 2022, excluding franchise-sale proceeds or financing.
- The company highlighted positive preclinical VYN201 data, first-patient enrollment in FMX114, and continued progress toward divesting the topical minocycline franchise.
VYNE reported third-quarter 2021 revenue of $4.1 million, consisting of $4.0 million of product sales from AMZEEQ and ZILXI and $21 million of royalty revenue. GAAP net loss was $21.3 million, or $0.41 per share; adjusted net loss was $18.9 million, or $0.36 per share after excluding $2.4 million of stock-based compensation expense. Adjusted operating expenses were $18.4 million, including adjusted SG&A of $11.9 million and adjusted R&D of $6.5 million, and were $1.9 million lower than Q2 2021. Cash was approximately $53 million at September 30, and management said that is expected to fund operations through the second quarter of 2022, excluding potential proceeds from the minocycline franchise sale, new business development transactions, or additional financing. For Q4 2021, adjusted operating expenses are expected to be $10 million to $15 million, excluding a one-time $4 million milestone payment tied to the VYN202 license agreement; for 2022, adjusted operating expenses are expected to be approximately $10 million per quarter.
Dave Domzalski framed the quarter as a continuation of VYNE’s strategic reset toward immuno-inflammatory disease, with the BET inhibitor platform now the centerpiece of the pipeline. He emphasized that VYN201 is planned to enter the clinic in 2022, that VYN202 remains in lead optimization with partner In4Derm, and that the company sees multiple early-stage milestones over the next 12 to 18 months. His tone was optimistic and forward-looking, but he repeatedly noted that program direction is still early and will be data-driven.
Tyler Zeronda focused on the improving cost structure and liquidity runway. He said adjusted operating expenses fell to $18.4 million in Q3, down $1.9 million from Q2, and guided to $10 million to $15 million in Q4 2021 excluding the $4 million VYN202 milestone payment. He also said cash of about $53 million should fund operations through Q2 2022, not counting any franchise-sale proceeds, business development transactions, or financing.
Analysts pressed management on likely indications for VYN201 and VYN202, how to think about topical versus oral use, and what would make FMX114 a go/no-go after the data reads out. Management said the BET programs are still early and that indication selection will be driven by data, though it mentioned rare dermatoses such as pyoderma gangrenosum for VYN201 and broader autoimmune/inflammatory areas such as RA, IBD/Crohn’s, and MS for VYN202. On FMX114, management said the Phase 1b portion is mainly to generate safety and PK data, with top-line results expected in early Q1 and PK data before year-end; the study’s primary endpoint is change in atopic dermatitis severity index.
The call suggested VYNE now has a cleaner strategic focus, with management seeing BET inhibitors as a potentially differentiated platform and citing strong preclinical VYN201 data, including cytokine reductions and no apparent negative effect on skin repair. FMX114 has advanced into the clinic, and management sounded confident that its multimodal topical design could be differentiated in atopic dermatitis. The company also said it is seeing meaningful interest in the sale of the minocycline franchise, which could add optionality to the balance sheet.
The business still depends on early-stage assets, with VYN201 and VYN202 not yet in the clinic and FMX114 still only in Phase 1b/2a. Cash was only guided to last through Q2 2022 absent a franchise sale, new financing, or other transactions, so funding remains a constraint. Management also repeatedly emphasized that indication selection is not locked down yet, and the minocycline divestiture was still pending, leaving near-term execution and financing risk.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.9%
- Shares Outstanding
- 667.70K
- Float Shares
- 613.69K
of shares held by institutions
43 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deeter Investments Llp | 1.00M | 0 |
| Citadel Advisors LLC | 468.46K | ▼ 45.99K |
| Two Sigma Investments, LP | 438.82K | ▲ 12.41K |
| Vanguard Group Inc | 314.55K | ▲ 124.16K |
| Ikarian Capital, LLC | 264.91K | 0 |
| Two Sigma Advisers, LP | 163.10K | ▲ 106.50K |
| Susquehanna International Group, Llp | 118.96K | ▲ 61.17K |
| Rangeley Capital, LLC | 113.06K | ▼ 5.00K |
| Gsa Capital Partners Llp | 71.53K | ▲ 71.53K |
| Northern Trust Corp | 43.68K | ▲ 20.57K |
| Two Sigma Securities, LLC | 40.70K | ▲ 40.70K |
| Tower Research Capital LLC (Trc) | 12.99K | ▲ 9.47K |
Our VYNE coverage
Recent articles, reports, and earnings notes.
No research on VYNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VYNE report →Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
businesswire.com · Jul 27
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
globenewswire.com · Jul 23
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
globenewswire.com · Jul 21
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
globenewswire.com · Jul 10
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%
defenseworld.net · Apr 15
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
defenseworld.net · Mar 15
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February
defenseworld.net · Mar 11
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com · Dec 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.